ClinicalTrials.gg
CompletedNCT05001516Updated Apr 17, 2024

Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors

A Phase 1 interventional study of LM-302 in Advanced Solid Tumor, sponsored by Turning Point Therapeutics, Inc.. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-17.

Sponsored by Turning Point Therapeutics, Inc. (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2024, 2 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

A Phase I, First-in-Human, Open-Label, Dose Escalation and Expansion Study of LM-302 in Patients with CLDN18.2-Positive Advanced Solid Tumors

Read the detailed description

A Phase I, First-in-Human, Open-Label, Dose Escalation and Expansion Study of LM-302 in Patients with CLDN18.2-Positive Advanced Solid Tumors

The study schedule includes screening visit (28 days prior to accept the investigational medicinal product (IMP)), treatment visit (accept IMP for the first time to the end of treatment (EOT)/early withdrawal), and follow-up visit (28 days after the EOT/early withdrawal).

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

Turning Point Therapeutics, Inc. is the lead sponsor of 9 studies on the registry; 2 are open to participants now.

First submitted before Turning Point Therapeutics, Inc. became part of Bristol-Myers Squibb.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who are fully informed of the purpose, nature, method and possible adverse reactions of the study, and are willing to participate in the study and sign the form (ICF) prior to any procedure;
  • Aged ≥18 years old when sign the ICF, male or female;
  • (ECOG) performance status of 0-1, and no deterioration within 2 weeks prior to the first dose;
  • ≥ 3 months;
  • Phase Ⅰa (Dose Escalation): Subjects must have histological or cytological confirmation of recurrent or advanced solid tumors, and have progressed on standard therapy, or are intolerable for available standard therapy , or there is no available standard therapy. The advanced solid tumors include but not limit to gastric and gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma, pancreatic carcinoma, biliary tract carcinoma, colorectal carcinoma, ovarian carcinoma.
  • Claudin18.2(CLDN18.2) status will be tested by central immunohistochemistry (IHC) testing for the enrolled subjects if the archived tumor tissue samples are available, and the enrolment is not dependent on the CLDN18.2's status.
  • CLDN18.2 positive may be required for the high dose levels as determined by Safety Monitoring Committee(SMC), the subjects need to have CLDN 18.2 positive available before enrolled and dosed, and the tumor types are limited to the types listed as phase Ib (Dose expansion).
  • Phase Ib (Dose Expansion): Subjects must have histological or cytological confirmation of recurrent or refractory CLDN18.2 positive* advanced solid tumors, and have progressed on standard therapy, or are intolerable for available standard therapy , or there is no available standard therapy. The advanced solid tumors include the following or the specific tumor types that are determined by SMC:
  • Gastric and gastroesophageal junction adenocarcinoma;
  • Pancreatic carcinoma;
  • Biliary tract carcinoma;
  • Colorectal carcinoma with known Microsatellite instability-high(MSI-H)/Different Mismatch Repair(dMMR);
  • Esophageal adenocarcinoma;
  • Ovarian mucinous carcinoma;

    *CLDN18.2-positive: defined as CLDN18.2 expression confirmed by central immunohistochemistry (IHC) test and with a staining intensity of 1+ to 3+ in ≥ 10% of the tumor cell. At least 3 subjects with a staining intensity of 2+ to 3+ in ≥ 40% of the tumor cells should be included for the dose expansion stage.

  • At least one evaluable lesion (including measurable and unmeasurable) for phase Ia dose escalation, and one for phase Ib dose expansion, according to v1.1;
  • Subjects must show appropriate organ and marrow function in laboratory examinations within 7 days prior to the first dose:
  • Bone marrow reserve: count (PLT) ≥ 90 × 109/L; (ANC) ≥ 1.5 × 109/L; ≥ 9 g/dL, without receiving Erythropoietin(EPO), G-Colony-Stimulating Factor(CSF), or Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) within 14 days and blood transfusion including red blood cell and platelet transfusion in at least 7 days prior to first dose;
  • Coagulation function: (INR) ≤ 1.5; Activated Partial Thromboplastin Time(APTT) ≤ 1.5 × ;
  • Liver function: Total ≤ 1.5 × ULN (Subjects with Gilbert's Syndrome are allowed if total bilirubin ≤ 3 × ULN); (AST) and Alanine Aminotransferase(ALT) ≤ 2.5 × ULN without liver (≤ 5 × ULN if liver metastases are present); Albumin ≥ 2.5 g/dL;
  • Kidney function: Serum creatinine ≤ 1.5 × ULN, or ≥ 50 mL/min (using Cockcroft-Gault formula);
  • Cardiac function: (LVEF) ≥ 50%; (QTcF) ≤ 480 ms;
  • Subjects who are able to communicate we

Exclusion criteria

Exclusion Criteria:

  • Exposure to any IMP, or participate in any other clinical trial within 21 days prior to 1st dosing of LM-302;
  • Subjects with anti-tumor treatment within 21 days prior to 1st dosing of LM-302, including radiotherapy, chemotherapy, biotherapy, endocrine therapy and immunotherapy, etc. Following treatments have different time limits:
  • Local small-scale palliative radiotherapy (bone radiotherapy to control pain) within 14 days prior to 1st dosing;
  • Oral anti-tumor therapy, including fluorouracil antitumor drugs and small molecular targeted drugs, etc. within 14 days or 5 half-life of the drug (whichever is shorter) prior to 1st dosing;
  • Traditional Chinese medicine with anti-tumor indication within 14 days prior to 1st dosing.
  • Nitrosourea or Mitomycin C within 42 days prior to 1st dosing.
  • Any adverse event from prior anti-tumor therapy has not yet recovered to ≤ grade 1 of v5.0 (Except for toxicities without safety risk judged by the investigator, such as alopecia, and other ≤ grade 2 long term toxicities);
  • Pre-existing peripheral sensory or motor neuropathy ≥ Grade 2;
  • Subjects with uncontrolled tumor-related pain. Subjects requiring analgesic treatment must be on a stable regimen before participating in the study. Symptomatic lesions amenable by palliative radiotherapy (e.g., bone metastases or metastases causing nerve damage) should be treated prior to enrolment. For the asymptomatic metastatic lesions whose further growth would likely cause functional defects or intractable pain, if appropriate, local treatment should be considered before enrolment;
  • Subjects with known central nervous system (CNS) or meningeal metastasis;
  • Subjects who have uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures;
  • Subjects who are allergic or hypersensitive to LM-302 (The are L-Glutamic acid, L-Arginine, Trehalose dihydrate and polysorbate 80 (for injection)) or similar products;
  • Subjects who have received the treatment targeting to CLDN18.2 or Monomethyl Auristatin E(MMAE) based Antibody-Drug Conjugates (ADCs):
  • Subjects who have received the treatment with ADCs targeting to CLDN18.2 are not eligible;
  • Subjects who were intolerable to the treatment with MMAE based ADCs or anti-CLDN18.2 antibodies are not eligible, but can be enrolled if they were tolerable to the treatments and have experienced a 28-day's prior to 1st dosing of LM-302;
  • For Phase Ib (Dose Expansion), subjects who were not response to the treatment with MMAE based ADCs or anti-CLDN18.2 antibodies are not eligible;
  • Administrate strong inhibitors/strong inducers of within 14 days prior to 1st dosing of LM-302;
  • Subjects with known active keratitis or corneal ulcerations. Subjects with superficial punctate keratitis are allowed if the disorder is being adequately treated in the opinion of the investigator.
  • Use of any (e.g., against infectious diseases such as influenza, varicella, COVID-19, etc.) within 28 days prior to 1st dosing of LM-302;
  • Subjects with the history of interstitial lung disease or drug-induced interstitial lung disease/pneumonitis;
  • Subjects who are taking therapeutic doses of anticoagulants such as heparin or vitamin K antagonists (except for preventive treatment at a stable dose);
  • Subjects with gastric outlet obstruction, persistent recurrent vomiting or uncontrolled/severe gastrointestinal hemorrhage, or ulcer within 28 days prior to 1st dosing of LM-302;
  • Subjects who received major surgery or interventional treatment within 28 days prior to 1st dosing of LM-302 (excluding tumor , puncture, etc.);
  • Subjects who have other active which are likely to require the treatment;
  • Subjects who have severe cardiovascular disease, including but not limited to:
  • Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmia requiring clinical intervention, and II-III degree atrioventricular block, etc.;
  • Thromboembolic events requiring therapeutic anticoagulation, or equipped with venous filters;
  • Cardiac insufficiency of grade III\~IV according to the (NYHA) standards;
  • Acute coronary syndrome, congestive heart failure, aortic dissection, stroke, or other cardiovascular and cerebrovascular events of grade 3 or above occurred within 6 months prior to 1st dosing of LM-302;
  • Clinically uncontrollable hypertension;
  • Subjects who have uncontrolled or severe illness, including but not limited to ongoing or active infection (e.g., active Corona Virus Disease 2019(COVID-19)/Severe Acute Respiratory Syndromes(SARS)-COVID-2 infection, etc.) requiring antibiotics and/or other therapeutic administration, while SARS-COVID-2 testing is not mandatory for study entry, and the testing should follow local clinical practice guidelines/standards.
  • Subjects who have a history of immunodeficiency disease, including other acquired or congenital immunodeficiency diseases, or organ transplantation, or bone marrow transplantation, or autologous hematopoietic stem cell transplantation;
  • infection, active Virus(HBV) and Virus(HCV)infection, with the exception:
  • Subjects with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-hepatitis B core(HBc)] and absence of HBsAg), as well as with normal liver function are eligible. Otherwise, if HBV infection was indicated, those with HBV DNA \< 500 IU/ML (or equivalent level) and normal liver function, combined with clinical manifestations, judged by the investigator to exclude active infection can be enrolled;
  • Subjects with positive HCV antibody but negative hepatitis C virus RNA test results and normal liver function are eligible.
  • female who have positive results in pregnancy test or are lactating;
  • Subjects who have psychiatric illness or disorders that may preclude study compliance;
  • Subject who is judged as not eligible to participate in this study by the investigator.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    LM302 Dose Escalation Level 1, 0.2 mg/kilogram(kg),

    The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses. first dose: 0.2mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=1;

    Drug: LM-302

  • Experimental
    LM302 Dose Escalation Level 2, 0.4 mg/kg

    The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses. second dose: 0.4mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=3;

    Drug: LM-302

  • Experimental
    LM302 Dose Escalation Level 3, 0.8 mg/kg

    The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses. third dose: 0.8mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=6;

    Drug: LM-302

  • Experimental
    LM302 Dose Escalation Level 4, 1.6mg/kg

    The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses. fourth dose: 1.6mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=6;

    Drug: LM-302

  • Experimental
    LM302 Dose Escalation Level 5, 2.4mg/kg

    The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses. fifth dose: 1.6mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=9;

    Drug: LM-302

  • Experimental
    LM302 Dose Escalation Level 6, 2.8mg/kg

    The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses. sixth dose: 1.6mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=12;

    Drug: LM-302

Interventions

  • DrugLM-302

    All subjects will be administered every 3 weeks (1 cycle=21 days) with a dose of LM-302 intravenous infusion on day 1 until meet the criteria of treatment discontinuation or withdraw, whichever occurs earlier.

06

What researchers measure

Primary outcomes

  1. Dose limiting toxicity (DLT)

    DLT is defined as a toxicity (adverse event at least possibly related to LM302) occurring during the DLT observation period

    Time frame: Cycle 1 of each cohort. Duration of one cycle is 21 days

  2. Number of participants with adverse events and serious adverse events

    The safety profile of LM302 will be assessed by monitoring the adverse events (AE) per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0

    Time frame: From the first administration in Cycle 1 date 1(C1D1)up to 1 year

  3. Change in Vital Signs-ear temperature

    Change in vital signs-ear temperature will be measured after the subject has been fully rested

    Time frame: Baseline C1D1through approximately 1 year after first administration of LM302

  4. Change in Vital Signs-pulse rate

    Change in vital signs-pluse rate will be measured after the subject has been fully rested.

    Time frame: Baseline C1D1through approximately 1 year after first administration of LM302

  5. Change in Vital Signs-systolic pressure

    Change in vital signs-systolic pressure will be measured after the subject has been fully rested.

    Time frame: Baseline C1D1through approximately 1 year after first administration of LM302

  6. Change in Vital Signs-diastolic blood pressure

    Change in vital signs-diastolic blood pressure will be measured after the subject has been fully rested.

    Time frame: Baseline C1D1through approximately 1 year after first administration of LM302

  7. Change in Physical examination-weight

    Change in Physical examination-weight will be measured with only light clothes

    Time frame: Baseline C1D1through approximately 1 year after first administration of LM302

  8. Incidence of Abnormal Clinical Laboratory Test Results-hematology

    Number of participants with incidence of abnormal clinical lab test results like hematology will be assessed.

    Time frame: Baseline C1D1through approximately 1 year after first administration of LM302

  9. Incidence of Abnormal Clinical Laboratory Test Results-Biochemistry

    Number of participants with incidence of abnormal clinical lab test results like Biochemistry will be assessed

    Time frame: Baseline C1D1through approximately 1 year after first administration of LM302

  10. Incidence of Abnormal Clinical Laboratory Test Results-Urinalysis

    Number of participants with incidence of abnormal clinical lab test results like Urinalysis will be assessed.

    Time frame: Baseline C1D1through approximately 1 year after first administration of LM302

  11. Incidence of Abnormal Clinical Laboratory Test Results-Coagulation test

    Number of participants with incidence of abnormal clinical lab test results like Coagulation test will be assessed

    Time frame: Baseline C1D1through approximately 1 year after first administration of LM302

  12. Change in Electrocardiogram (ECG)-(R wave)RR interval

    RR interval of 12-lead ECG will be performed in the supine position after the patients are fully rested at each timepoint for once. RR is the standard heart rate which calculated by 60 divided by heart rate.

    Time frame: Baseline C1D1through approximately 1 year after first administration of LM302

  13. Change in Electrocardiogram (ECG)-QT interval

    QT interval of 12-lead ECG will be performed in the supine position after the patients are fully rested at each timepoint for once.

    Time frame: Baseline C1D1through approximately 1 year after first administration of LM302

  14. Change in Electrocardiogram (ECG)-QRS duration

    QRS duration of 12-lead ECG will be performed in the supine position after the patients are fully rested at each timepoint for once.

    Time frame: Baseline C1D1through approximately 1 year after first administration of LM302

Secondary outcomes

  1. Area under the serum concentration versus time curve within one dosing interval (AUCtau)

    Blood samples will be collected at time points of 0 h, immediately after infusion stop, as well as at 1 h,4 h, 8 h, 24 h, 48 h (Day 3), 168 h (Day 8), and 336 h (Day 15) after infusion stop in cycle 1 and cycle 4; 0 h in cycle 2, cycle 3 and cycle 5; pre-dose (0 h) will be collected in every other cycle for the subsequent cycles. i.e., in cycle 6, cycle 8, ... etc.; at EOT/early withdraw from the study (if the EOT/early withdraw occur when PK blood sampling isn't stipulated). The timepoints of PK sample may be adjusted base on the human PK data. The blood samples for PK analysis will be collected as much as possible if the subjects end of treatment/early withdraw.

    Time frame: Up to 1 year

  2. Volume of distribution at steady state (Vss)

    To determine the pharmacokinetics (PK) profile of LM302

    Time frame: Up to 1 year

  3. Maximum serum concentration (Cmax)

    To determine the pharmacokinetics (PK) profile of LM302

    Time frame: Up to 1 year

  4. Minimum serum concentration(Cmin)

    To determine the pharmacokinetics (PK) profile of LM302

    Time frame: Up to 1 year

  5. Time to reach maximum serum concentration (Tmax)

    To determine the pharmacokinetics (PK) profile of LM302

    Time frame: Up to 1 year

  6. Clearance (CL)

    To determine the pharmacokinetics (PK) profile of LM302

    Time frame: Up to 1 year

  7. Terminal half-life (T1/2)

    To determine the pharmacokinetics (PK) profile of LM302

    Time frame: Up to 1 year

  8. Dose proportionality

    To determine the pharmacokinetics (PK) profile of LM302

    Time frame: Up to 1 year

  9. Objective response rate of LM-302.

    Preliminary anti-tumor activity of LM-302 according to RECIST v1.1 assessed by investigator: objective response rate (ORR, complete response(CR)+ partial response(PR))

    Time frame: Up to 1 year

  10. Duration of response of LM-302.

    Preliminary anti-tumor activity of LM-302 according to RECIST v1.1 assessed by investigator: Duration of response (DOR)

    Time frame: Up to 1 year

  11. Disease control rate of LM-302.

    Preliminary anti-tumor activity of LM-302 according to RECIST v1.1 assessed by investigator: disease control rate (DCR, CR+PR+SD)

    Time frame: Up to 1 year

  12. Progression-free survival of LM-302.

    Preliminary anti-tumor activity of LM-302 according to RECIST v1.1 assessed by investigator:progression-free survival (PFS)

    Time frame: Up to 1 year

  13. To assess the immunogenicity of LM-302;

    Blood samples collected for Anti-Drug Antibody(ADA) assessment will be performed at 0 h of Day 1 (within 30 min prior to infusion) in cycle 1 to Cycle 5; 0 h of Day 1 in every other cycle (within 30 min prior to infusion) for the subsequent cycles, i.e., in cycle 6, cycle 8, ... etc., the EOT/early withdraw from the study and safety follow-up. Nab will be detected if necessary.

    Time frame: Up to 1 year

Other outcomes

  1. To explore the correlation between CLDN18.2 expression and anti-tumor activity of LM-302

    Test CLDN18.2 expression and anti-tumor activity of LM-302

    Time frame: Up to 2 years

07

Study locations

7 sites
  • Local Institution - 0013
    Duarte, California 91010, United States
  • Local Institution - 0017
    Fullerton, California 92835, United States
  • Local Institution - 0012
    Lafayette, Indiana 47905, United States
  • Local Institution - 0020
    Paramus, New Jersey 07652, United States
  • Local Institution - 0018
    New York, New York 10016, United States
  • Local Institution - 0016
    Oklahoma City, Oklahoma 73120, United States
  • Local Institution - 0015
    Houston, Texas 77030, United States
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Jan 2024, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2021
First posted
Aug 12, 2021
StartActual
Dec 29, 2021
Primary completionActual
Jan 4, 2024
CompletionActual
Jan 4, 2024
Last update
Apr 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05001516
Responsible party
Sponsor
First posted
Aug 12, 2021
Start date
Dec 29, 2021
Primary completion
Jan 4, 2024
Completion
Jan 4, 2024
Last update
Apr 17, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tecotabart vedotin

Start the discussion